Cancer Care

 

 
A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPPORT) In Prostate Cancer Patients With A Rising Psa After Radical Prostatectomy
Principal Investigator (?)
Study Number
R0534
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can
cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide,
bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen the amount of
androgens made by the body. It is not yet known which regimen of radiation therapy with or
without androgen-deprivation therapy is more effective for prostate cancer.

PURPOSE: This randomized phase III trial is studying prostate radiation therapy to see how
well it works compared with short-term androgen deprivation therapy given together with
pelvic lymph node radiation therapy with or without prostate radiation therapy in treating
patients with a rising PSA after surgery for prostate cancer.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Keene
Lebanon
St. Johnsbury, VT

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.